Gillam Mary P, Fideleff Hugo, Boquete Hugo R, Molitch Mark E
Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA, and Endocrinology Unit, Alvarez Hospital, Buenos Aires, Argentina.
Pediatr Endocrinol Rev. 2004 Nov;2 Suppl 1:108-14.
Dopamine agonists provide highly effective therapy for the treatment of hyperprolactinemia. As a result of their efficacy and tolerability, these agents are considered to be the initial therapy of choice in children, adolescents and adults with idiopathic hyperprolactinemia and prolactinomas. The four dopamine agonists, bromocriptine, pergolide, cabergoline and quinagolide, share a similar mechanism of action and side effect profile. Although studies of cabergoline have demonstrated the highest treatment efficacy and tolerability, all four of these agents are safe, effective and tolerable in children and adolescents. When fertility is desired, bromocriptine is generally preferable, but cabergoline is also likely safe; pergolide and quinagolide should not be used in this setting.
多巴胺激动剂为高泌乳素血症的治疗提供了高效疗法。鉴于其疗效和耐受性，这些药物被视为患有特发性高泌乳素血症和泌乳素瘤的儿童、青少年及成人的首选初始治疗药物。四种多巴胺激动剂，即溴隐亭、培高利特、卡麦角林和喹高利特，具有相似的作用机制和副作用特征。尽管对卡麦角林的研究已证明其具有最高的治疗效果和耐受性，但这四种药物在儿童和青少年中均安全、有效且耐受性良好。若有生育需求，通常更倾向使用溴隐亭，但卡麦角林可能也安全；在这种情况下不应使用培高利特和喹高利特。
